Protagonist Therapeutics, Inc
Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities, rusfertide and PN-235, in different stages of clinical development, both derived from the Company's proprietary technology platform. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate. VERIFY, the global Phase 3 registrational study of rusfertide in polycythemia vera, is currently underway.